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ABSTRACT
DMP1 mutations in autosomal recessive hypophosphatemic rickets (ARHR) patients and mice lacking Dmp1 display an overlapping
pathophysiology, such as hypophosphatemia. However, subtle differences exist between the mouse model and human ARHR patients.
These differences could be due to a species specificity of human versus mouse, or it may be that the mutant DMP1 in humans maintains
partial function of DMP1. In this study we report a deformed tooth phenotype in a human DMP1 deletion mutation case. Unexpectedly,
the deletion of nucleotides 1484 to 1490 (c.1484_1490delCTATCAC, delMut, resulting in replacement of the last 18 residues with 33
random amino acids) showed a severe dentin and enamel defect similar to a dentinogenesis imperfecta (DI) III–like phenotype. To
address the molecular mechanism behind this phenotype, we generated delMut transgenic mice with the endogenous Dmp1 gene
removed. These mutant mice did not recapture the abnormal phenotype observed in the human patient but displayed a mild rachitic
tooth phenotype in comparison with that in the Dmp1-null mice, suggesting that the DI III–like phenotype may be due to an as-yet-
undetermined acquired gene modifier. The mechanism studies showed that the mutant fragment maintains partial function of DMP1
such as stimulating MAP kinase signaling in vitro. Last, the in vitro and in vivo data support a role of odontoblasts in the control of
fibroblast growth factor 23 (FGF-23) regulation during early postnatal development, although this regulation on Pi homeostasis is likely
limited.  2010 American Society for Bone and Mineral Research.
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Introduction
M
utations in fibroblast growth factor 23 (FGF23) and PHEX
account for approximately 60% of hypophosphatemic
rickets with eucalciuria and are associated with abnormalities in
dentin and bone.
(1) Mutations in the type 2a sodium-phosphate
cotransporter lead to hereditary hypophosphatemic rickets with
hypercalciuria (HHRH).
(2-6) The molecular defects responsible for
the remaining hypophosphatemic patients are unknown.
Previously, we reported that Dmp1-null newborns displayed
no gross phenotype
(7) but developed hypophosphatemia includ-
ing hypomineralized bone,
(8) defects in chondrogenesis,
(9) partial
failure of predentin maturation into dentin, and expansion of the
pulp cavities and root canals during postnatal tooth develop-
ment.
(10) These data support a dual role of DMP1 in both local
and systemic regulation of phosphate (Pi) homeostasis.
(11,12)
WeandothersalsoreportedthatDMP1mutationsareresponsible
forautosomalrecessivehypophosphatemicrickets (ARHR) inhuman
patients,includingbonedefectsandanincreaseinfibroblastgrowth
factor 23 (FGF-23) levels (although some of DMP1 mutation patients
overlappedwiththenormalrangeforFGF-23).
(12-14)However,there
is a phenotypic difference between human patients (mild) and
Dmp1-null mice (severe). These differences could be due to a
species specificity of human versus mouse or to the fact that the
mutant fragment may maintain partial DMP1 function. Further-
more, few clinical cases of ARHR have been reported so far;
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2155therefore, it is challenging to obtain human cases for pathophy-
siologic studies.
(12,13,15) Thus generation of DMP1 mutant mouse
models based on the human mutations is critical not only for
distinguishing these differences but also for molecular patho-
physiologic studies of this disorder.
ThetoothphenotypeinourpreviouslyreportedARHRcases
(12)
has not been reported. DMP1, highly expressed in odontoblast
(7)
and osteocyte cells,
(16) is cleaved into N-terminal and C-terminal
fragments,
(11) but it is not clear which fragment is functionally
critical for bone and tooth formation both in vivo and in vitro.
The goals of this study were (1) to report the DMP1 mutant
tooth phenotype from one of our previously reported clinical
cases,
(12) (2) to determine the molecular genetics and patho-
physiology of DMP1 mutations through generation and analysis
of a mouse model harboring the DMP1 deletion mutation
comparedwithDmp1-nullmice,(3)tounderstandhowtheDmp1
mutant changes cell signaling in vitro, (4) to determine whether
Dmp1-null or Dmp1 delMut mice develop an enamel phenotype,
and (5) to test whether odontoblast cells play a role in control of
FGF23 expression.
Materials and Methods
Human subjects
Dental radiographs were obtained from one individual with
ARHR owing to the delMut described previously (patient F1-2).
(12)
Patient F1-2 had unique clinical features that distinguished her
from the other hypophosphatemic patients in these kindreds,
including global developmental delay and a seizure disorder. To
date, it remains unclear whether these additional features are
linked to the delMut in DMP1; however, their presence in a
single patient who has two affected siblings without these
features raises the likelihood that they are not part of the ARHR
phenotype.
Generation of mutant Dmp1 transgenic mice
A full-length mouse Dmp1 cDNA was cloned, and 7 nucleotides
corresponding to the 1484-1490del mutation of human DMP1 in
ARHR patients
(12) were deleted by site-directed mutagenesis
using the QuikChange II Site-Directed Mutagenesis Kit (Strata-
gene, La Jolla, CA, USA) with primers DMUT-F (GAAACTAA-
TAGTTGATGCAACAAA CCCATTGGGGACCAAGATG) and DMUT-R
(CATCTTGGTCCCCAATGGGTTTGTTGCATCAACTATTAGTTTC). For
generation of a mutant Dmp1 transgene, the full-length mouse
Dmp1 cDNA with the 7-nucleotide deletion and an SV40
polyadenylation signal were cloned into a mammalian expres-
sion vector
(17) (graciously provided by B Kream and A Lichtler,
University of Connecticut Health Center, Farmington, CT, USA)
containing the 3.6-kb rat type I collagen promoter plus a 1.6-kb
intron 1 (Col1a1 promoter) that is highly active in pulp cells,
odontoblasts, and osteoblasts, giving rise to the Col1a1-mutant
Dmp1 transgene. The transgene was released by SacII and SalI
from the vector backbone and purified for pronuclear injection.
Transgenic founders with CD1 background were generated.
Threeoffiveindependenttransgeniclineswereusedforcrossing
to Dmp1-null mice (see below).
Target expression of the mutant Dmp1 transgene in
Dmp1-null mice
We have previously described the generation of Dmp1-null mice
using the lacZ knock-in targeting approach.
(7) For expression of
the mutant Dmp1 transgene in Dmp1-null mice, Col1a1-mutant
Dmp1 transgenic mice were first crossed with heterozygous
(HET) Dmp1-null mice to generate HET Dmp1-null mice with the
Col1a1-mutant Dmp1 transgene (Tg
þ/–;Dmp1
þ/–). These mice
were further bred with homozygous Dmp1-null mice to generate
homozygousDmp1-nullmicecarryingthemutantDmp1transgene
(Tg
þ/–;Dmp1
–/–).Thismouselineisdesignatedmutantmouse(Mut).
Since no phenotypic differences between the wild-type and
heterozygous Dmp1-null mice were found.
(9,10) the littermate HET
Dmp1 mice were used for control.
The two Dmp1 transgenic mouse lines
(18) Col1a1P-Dmp1
transgene (under the control of the same promoter as used for
drivingthemutantDmp1transgene)andDsppP-Dmp1transgene
(under control of the 6-kb mouse Dspp promoter, actively
expressed only in late odontoblast cells)
(19) were crossed into
Dmp1-null mice.
(7) Samples of three developmental stages (10
days old, 3 weeks old, and 2 months old) were obtained and
analyzed for this study. All mice were bred to a CD1 background,
an outbred strain for getting closer to the physiologic condition.
The animal research has complied with all relevant federal
guidelines and institutional policies.
PCR genotyping
Genomic DNA was extracted from a tail biopsy and used for
genotyping by PCR analysis. Primers p01 (5’-GAGTGCGATCTTCCT-
GAGGCCGATACTGTC-3’) and p02 (5’-CGCGGCTGAAATCATCAT-
TAAAGCGAGTGG-3’)w e r eu s e df o rd e t e c t i o no ft h eDmp1-null
allele (490 bp), and primers p03 (5’-GCCCCTGGACACTGACCA-
TAGC-3’)a n dp 0 4( 5 ’-CTGTTCCTCACTCTCACTGTCC-3’)w e r eu s e d
for detection of the wild-type allele (421 bp). The primers p05 (5’-
CAGCCGTTCTGAGGAAGACAGTG-3’from Dmp1 cDNA) and p06(5’-
TGTCCAAACTCATCAATGTATCT-3’ from the SV40 polyadenylation
signal) were used for detection of the wilt-type (WT) or mutant
Dmp1 transgene (337 or 330 bp, respectively).
High-resolution tooth radiography and micro–computed
tomography (mCT)
Themandiblesamplesfromcontrol,Dmp1-null,andmutantmice
were dissected free of muscle, and the first molars of the maxilla
were extracted as described previously.
(10) Briefly, fresh mandibles
wereincubatedinlysisbuffer(2 SSC,0.2%SD S,10m MED TA ,a nd
1mg/mL proteinase K) for 1 to 2 days at 558C. After the muscles
surrounding teeth were digested,the molars were extracted under
adissectionmicroscope.Theintactmandiblesandfirstmolarsthen
were examined radiographically using a high-resolution radio-
graphysystem(piXarray100,MicroPhotonics,Allentown,PA,USA).
mCTanalysesincludealow-resolutionscanofonehemimandible
per animal for overall assessment of shape and structure and
a high-resolution (6-mm) scan of a more limited anatomic area
(200 slices) in a specified region of interest for detailed 3D
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AG, Bru ¨ttisellen, Switzerland).
Histologic preparation
Mandible specimens from control, Dmp1-null, mutant, and
rescued mice were dissected and fixed in 4% paraformaldehyde
at 48C overnight, followed by two different processes: (1) One
side specimens were decalcified, dehydrated, and embedded in
paraffin and then sectioned for in situ hybridization, hematoxylin
and eosin (H&E) staining, and safranin-O staining, and (2) the
othersidespecimensweredehydrated andembeddedinmethyl
methacrylate, and nondecalcified sections were used for dentin
formation rate and scanning electron microscopy (SEM).
In situ hybridization
The mouse antisense RNAs for Dmp1, Fgf23, and Phex were used
for in situ hybridization, as described previously.
(16) Briefly,
digoxigenin (DIG)–labeled mouse cRNA probes were prepared
by using an RNA Labeling Kit (Roche, Indianapolis, IN, USA). The
hybridization temperature was set at 558C, and the washing
t e m p e r a t u r ew a ss e ta t7 0 8C so that endogenous alkaline phosphatase
was inactivated. DIG-labeled nucleic acidswere detected in an enzyme-
linked immunoassay with a specific anti-DIG-AP antibody conjugate
and an improved substrate that gives rise to a red signal (Vector,
Burlingame, CA, USA) according to the manufacturer’s instructions.
Double fluorochrome labeling
To examine the dentin formation rate, double fluorescence
labeling was performed as described previously.
(12,18) Briefly, an
alizarin red label (20mg/kg i.p.; Sigma-Aldrich, St. Louis, MO,
USA) was administered to 12-day-old mice, followed by
administration of a calcein label (5mg/kg i.p.; Sigma-Aldrich)
7 days later. Mice were euthanized 2 days after the second
injection (3 weeks old). The nondecalcified upper mandibles
were sectioned, and unstained sections were photographed
under epifluorescence illumination using a Nikon E800 micro-
scope (Nikon Instruments, Melville, NY, USA).
Generation of recombinant DMP1 proteins, cell cultures,
stains-all staining, and Western blot
The full-length DMP1, C-terminal DMP1, and full-length delMut
DMP1cDNAs were cloned originally into the pcDNA3 vector.
(20)
The empty pcDNA3 vector, pcDNA3-WT DMP1 vector, and
pcDNA3-delMutDMP1vector,weretransfectedinto293celllines
for 24hours, followed by serum-free medium culture for another
24hours for confirming their secretion in the medium. Then 5mL
of condition medium was loaded to 4% to 20% gradient
polyacrylamide gels, followed by staining with stains-all staining
agent, as described previously.
(21)
The full-length DMP1, C-terminal DMP1, and full-length delMut
DMP1 cDNAs were released from the pcDNA3 vector and r-
cloned into the PGEX4T-2 vector separately. These vectors then
were transformed into the bacterial host BL21 for production of
recombinant DMP1-Glutathione S-transferase fusion proteins,
followed by removal the GST tag using thrombin (Sigma-Aldrich)
according to the manufacturer’s recommendations. For testing
the effects of these recombinant DMP1s on MAPK signaling, an
odontoblast cell line
(22)wasgrownto70%confluency. Cellswere
serum-deprived for 16hours prior to recombinant DMP1
treatment. Cells were treated in triplicate with 250ng/mL of
full-length, C-terminal, or the delMut DMP1 and harvested at
different time points (0, 5, 10, 30, and 60minutes) for MAPK
activation. The concentration of cell lysates was determined by
using the BCA kit (Pierce, Rockford, IL, USA). Then 10mg of total
protein was subjected to 10% SDS-PAGE gel, followed by
blotting onto polyvinylidene difluoride membranes, and probed
with the following antibodies: anti-phosphorylated-ERK (p-ERK),
ERK, and b-actin (used at 1:1000 dilution; Cell Signaling
Technology,Danvers,MA,USA).TheWesternblotwasperformed
using chemiluminescence (Perkin Elmer, Waltham, MA, USA) of
horseradish peroxidase (HRP) linked to a second antibody (Cell
Signaling, Inc.). The membranes then were exposed to X-Omat
Kodak film (Perkin Elmer) to visualize the bands.
Real-time RT-PCR
Newborn primary calvarial and pulp cells were isolated and
culturedfor48hours,followedbyreal-timeRT-PCRforquantitation
of Fgf23 mRNA. Briefly, total RNA was extracted by using a Trizol
reagent (Invitrogen, Carlsbad, CA, USA). Freshly isolated RNA was
reverse transcribed with a Super Script first-strand synthesis
system (Invitrogen) following the manufacturer’sr e c o m m e n d a -
tions.TheresultingcDNAthenwassubjectedtoquantitativereal-
time PCR using 2  Brilliant SYBR QPCR Green Master Mix
Reagent (Stratagene, Cedar Creek, TX, USA). The sequences of
the primers were for Fgf23,5 ’-TACTTGTCGCAGAAGCATCAC-3’ and
5’-GGCGAACAGTGTAGAAATGCAG-3’,a n df o rGapdh,5 ’-ACCA-
CAGTCCATGCCATCAC-3’ and 5’-TCCACCACCCTGTTGCTGTA-3’.
Three independent measurements per sample were performed.
The quantified individual RNA expression levels were normalized
to Gapdh.
Serum biochemistry
Ten-day-, 3-week-, and 2-month-old male mice were anesthe-
tized, blood was collected though heart puncture, and serum
samples were obtained by precipitation and centrifugation.
Serum Pi levels were measured using a Phosphorus Liqui-UV Kit
(StanbioLaboratory, Boerne, TX,USA). Serumcalcium levels were
assayed using a Calcium Liquicolor Kit (Stanbio Laboratory)
following the manufacturer’s protocol. Serum intact FGF-23
levels were measured using an FGF-23 ELISA Kit (Kainos
Laboratories, Tokyo, Japan), as described previously.
(12)
Statistical analysis
Data were expressed as the mean SEM. Data were evaluated
statistically by ANOVA to test for any differences among the
three groups of mice. If significant differences were found by
ANOVA, the Bonferroni method of multiple comparisons was used
to determine which groups were significantly different from each
other.Apvalueoflessthan.05isconsideredstatisticallysignificant.
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DMP1 deletion mutation led to DI III–like tooth
phenotype
Previously, we reported that the deletion of nucleotides 1484 to
1490 of DMP1 (delMut) resulted in the last 18 amino acids being
replacedby33nonnativeresidues
(12)(Fig.1A).Aradiographfrom
a delMut child at age 3þ showed significantly enlarged pulps
and root canals with extremely thin dentin and loss of enamel
(Fig. 1B, upper right panel, white arrows) in comparison with an
age-matched control child (Fig. 1B, upper left panel). At age 10,
the same child showed a DI III–like phenotype, including the
following features: lack of well-mineralized dental enamel,
enlarged pulp chamber, and enlarged root canal, which are likely
a result of decreased dentin formation as well as malformed
tooth shape (Fig. 1B, lower panels).
The severe tooth phenotype, affecting both dentin and
enamel, in the delMut patient raised the following questions:
Is the tooth phenotype a primary consequence of the DMP1
mutation orthe result of adominant-negative roleof this mutant
or other events trigged by the DMP1 mutant? The simplest way
to address this dilemma is to generate a delMut mouse model
mimicking the same mutation observed in human patients and
to test whether this deletion mutation will recapture the same
tooth phenotype in mice.
Overexpression of delMut transgene driven by a 3.6-kb
Col1a1 promoter in a wild-type background has no
apparent phenotype
To generate a delMut mouse model harboring the human DMP1
1484-1490del mutation, we first generated a transgenic mouse
harboring a full-length Dmp1 cDNA with the same deletion
mutation as observed in the patients under the control of a
3.6-kb Col1a1 promoter, which is highly active in pulp cells,
odontoblasts, and osteoblasts.
(17,23) Previously, we have success-
fully rescued the Dmp1-null tooth phenotypes using the full-
length Dmp1 cDNA under the control of the same promoter
(18);
thus this promoter might have the proper spatial-temporal
characteristics to mimic the endogenous Dmp1 gene expression
in teeth. Five independent Col1a1-mutant Dmp1 transgenic lines
were obtained, and three independent lines were used for this
study. These three lines (2, 11, and 21) have different expression
levels (see the RT-PCR data in Supplemental Fig. 1), although
none of these lines shows an apparent phenotype (data not
shown),excludingadominant-negativeroleofthismutantinthe
WT background. In addition, all three lines in the Dmp1-null
background show an identical expression pattern, although only
line 2 is shown in Fig. 2A.
Dmp1 mutant mice display abnormalities in
dentinogenesis and condyle formation with little change
in enamel
Next, we crossed these three independent lines of the delMut
mice into the Dmp1-null background. All these independent
lines display an identical dentin-defect phenotype (see below),
although only one of the mutant lines is presented (line 2). Note
that we have previously reported that Dmp1-null mice displayed
a partial failure of maturation of predentin into dentin,
hypomineralization of the dentin, and expansion of the pulp
cavities and root canals during postnatal tooth development.
(10)
To determine whether the Dmp1 delMut mice display the
same phenotype as the mutant individual, the mutant (Fig. 2,
right panels), the Dmp1-null (Fig. 2, middle panels), and the
control mice (Fig. 2, left panels) were examined by a combination
of radiography, micro–computed tomography (mCT), histology,
and a double-labeling assay, as well as backscattered SEM. Like
Dmp1-nullmice,Dmp1mutantmiceshowedathindentinandan
enlarged pulp cavity and root canal with radiographic and mCT
analyses (Fig. 2B, C). Note that the quantitative analysis showed a
significant reduction of dentin in the Dmp1-null mice, with
p<.05 compared with the control, whereas the reduction in
dentin in the mutant is not significantly different from control
(Fig. 2C, lower panel).
Importantly, both the mCT image (Fig. 2C) and backscattered
SEMimages(Fig. 2D)showedidentical mineral densityandprism
structure in control, knockout, and mutant mice. High-resolution
3D mCT images showed that the root dentin is porous in the root
canals of both the Dmp1-null and delMut mice (Fig. 2E). H&E
staining showed similar changes: expanded predentin and thin
dentininbothDmp1-nullandDmp1mutantmicecomparedwith
control mice (Fig. 2F). The double-labeling assay also showed
similar reductions in dentin formation rate and diffused labeling
lines in both Dmp1-null and Dmp1 mutant mice (Fig. 2G). Lastly,
Fig. 1. Tooth phenotypes in a delMut ARHR patient. (A) A schematic
amino acid comparison of the end of the C-terminal region of the DMP1
gene among different species, including the 1484-1490del mutation
previously reported.
(12) The 1484-1490del mutation resulted in a frame-
shift that replaced the conserved C-terminal 18 residues with 33 non-
native residues. (B) Radiographs from a 3-year-old 1484-1490del
mutation patient (upper right panel) and an age-matched control (upper
left panel),aswellas radiographsfromthesamepatientat10yearsofage
(lower panels). Changes in tooth shape, severe reduction in dentin
thickness, large pulp/root canals, and loss of enamel are shown in both
primary and permanent teeth (arrows).
2158 Journal of Bone and Mineral Research JIANG ET AL.both Dmp1-null and mutant mice showed similar defects in
condyle formation, with expanded hypertrophic chondrocytes in
condyles (Fig. 2H, I).
Taken together, all the assays just described showed similar
defects in both Dmp1-null and mutant mice, supporting a
hypothesis that the delMut DMP1–targeted transgene recap-
tures the Dmp1-null dentin phenotype without an apparent sign
of enamel defects, although the mutant phenotype is slightly
milder than that of null mice.
The delMut DMP1–targeted transgene recaptures the
mild changes in serum FGF-23 and Pi levels
We previously reported that delMut patients display mild
changes in FGF-23 (<2-fold changes) and Pi levels (<20%
reduction) in comparison with the normal controls.
(12) In this
study we showed a mild increase in FGF-23 (2- to 3-fold) in
delMut mice compared with control (Fig. 3A). Similarly, the
change in Pi level also was mild in all three age groups
Fig. 2. The delMut Dmp1 recaptures the mild Dmp1-null dentin phenotype with no change in enamel. (A) In situ hybridization (red staining with green
nuclear counterstain) for Dmp1 in the lower first molar in 10-day-old mice. In the heterozygous control (HET), Dmp1 is expressed in odontoblasts (left
panels). In Dmp1 knockout (KO) mice, there is no Dmp1 signal (middle panels). In Dmp1-null mice with the deletion mutant (MUT) full cDNA reexpressed in
odontoblasts(undercontrolofthe3.6-kbCol1a1promoter),theMUTexpressionlevelisveryhigh(rightpanels).(B)Radiographsofthefirstuppermolarsof
HET(left),KO(center),andMUT(right)mice,withenlargedpulp/rootcanalsobservedinKOandmutantteeth.(C) CoronalsectionmCTviewsobtainedfrom
the first lower molars of HET (upper left), KO (upper center), and MUT (upper right) mice, exhibiting thin dentin and porous alveolar bone in KO (more
striking) and MUT (milder) teeth. Quantitative mCT data (lower panel) reveal a significant difference between HET and NULL groups (
 p<.05 by Student’s
t test, n¼4).The MUTgroupshows thesametrend but withno significancecomparedwith the HETgroup. (D) Backscattered SEM imagesshowthat there
is no an apparent difference in the enamel prism structure and distribution among control (left), KO (center), and MUT (right) groups. (E)3 DmCT images of
thefirst
tlowermolarsobtainedfromthesethreegroups,revealingporousdentinstructuresintheKO(center)andmutant(right)mice.(F)H&Estainsofthe
first lower molars, revealing a thin dentin layer and an enlarged predentin layer in KO (center) and MUT (right) mice. (G) Fluorochrome double-labeled
sections of the lower first molars, revealing reduction of the dentin mineralization rate plus diffused labeling lines in KO (center) and MUT (right) mice.
(H, I) The abnormalities of condyle formation in KO (center) and MUT (right) mice as documented with radiographs (F) and safranin O assays (I).
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unchanged in both Dmp1-null and delMut groups (Fig. 3C).
These data suggest that the delMut DMP1 has a partial function
of DMP1.
Roles of DMP1 recombinant proteins in activation of
MAPK signaling vary
Recently, Wu and colleagues (http://iadr.confex.com/iadr/
2008Dallas/techprogram/abstract_101678.htm) showed that
DMP1 targeted to avb-integrin and activated the MAPK-Erk
and Jnk-AP1 signaling pathways in vitro. To address the
molecular mechanism by which DMP1 or mutant DMP1 regulate
cellsignaling, wecomparedtheirefficiency inactivationofMAPK
signaling in an odontoblast cell line in vitro.
First, we generated the following three recombinant DMP1s:
full-lengthDMP1,57-kDaC-terminalfragmentDMP1,anddelMut
DMP1. The stains-all assay showed that these recombinant
proteins were secreted into the medium and that both the
delMut DMP1 and WT DMP1 were cleaved in vitro (Fig. 4A). Next,
we tested their efficiency in activation of MAPK signaling in an
odontoblast cell line.
(22) A ss h o w ni nF i g .4 B, all these recombinant
proteins activated phosphorylated ERK. However, the effect of the
57-kDafragment lasted for over 30minutes,the full-length protein
effectlasted for approximately 10minutes,and the delMutprotein
effect lasted for only 5minutes (see ‘‘Discussion’’ for details).
Odontoblast cells play a role in regulation of FGF-23
expression in vivo
FGF-23 has been demonstrated to be a critical physiologic and
pathophysiologic factor in control of phosphate homeostasis in
normal and several hypophosphatemic diseases.
(24,25) Previously,
we showed that FGF-23 is expressed mainly in osteoblasts in
normal bone and sharply increased in Dmp1-null osteocytes.
(12) To
address whether the odontoblast cells play a role in FGF-23
regulation, we first compared Fgf23 mRNA levels in newborn
primary calvarial cells and pulp cells using real-time RT-PCR and
showed a roughly 3-fold higher level in pulp cells than in calvarial
cells (Fig. 5A). Next, we tested the expression pattern of Fgf23
mRNA in 10-day-old odontoblasts using an in situ hybridization
assay. As shown in Fig. 5B, the basal level of Fgf23 mRNA in
control odontoblast cells is much higher than that in bone cells.
Second, we showed that the level of Fgf23 mRNA was sharply
increased in both Dmp1-null osteocytes and odontoblasts,
although the changes in the Dmp1-null osteocytes were more
striking than those in the Dmp1-null odontoblasts (Fig. 5C). Third,
we retargeted expression of WT Dmp1 in both null osteoblast/
osteocyte and odontoblast cells by crossing transgenic mice
harboring Dmp1 driven by the 3.6-kb Col1a1 promoter to Dmp1-
null mice (Fig. 5D). The level of Fgf23 mRNA was returned to the
control level in the rescued cells. Lastly, retargeting Dmp1 in the
Dmp1-null odontoblast cell by the Dspp promoter that is
activated mainly in odontoblast cells reduced the Fgf23 level in
the Dmp1-null tooth cell but not in the null bone cell (Fig. 5E).
Taken together, this information suggests that odontoblast cells
may play in control of FGF-23 level in a pathologic condition.
However, this role might be very limited in comparison with the
role of osteocytes.
(12)
Loss or overexpression of Dmp1 has no effects on
expressions of Phex mRNA in odontoblast cells in vivo
Both Dmp1 and Phex are coexpressed in bone and tooth.
Deletions of either gene in mice or mutations of DMP1 or PHEX in
human patients display an identical hypophosphatemic rickets
phenotype.
(9,10,24,26) It has long been thought that there might
be interactions between PHEX and DMP1 in some manner. To
address this issue, we first confirmed Phex mRNA expression in
odontoblast cells (Fig. 6A). Next, we analyzed Phex expression
levels in Dmp1-null odontoblast cells with or without targeted
reexpression of Dmp1 in the Dmp1-null odontoblasts. Our results
showed that Phex mRNA levels were largely unchanged,
excluding the effects of Dmp1 on Phex expression in the
odontoblast cell (Fig. 6B–D).
Discussion
Herewehaveusedaclinicalcaseandloss,gain,andmutantanimal
models,aswell as acombinationofX-ray, mCT, backscattered SEM,
Fig. 3. Serum changes in FGF-23, Pi, and Ca in Dmp1-null and delMut
mice. (A) Changes in serum FGF-23 at 3 weeks and 2 months of age.
(B) Changes in serum Pi at 10 days, 3 weeks, and 2 months of age.
(C) No apparent changes in serum Ca at 10 days, 3 weeks, and 2 months
of age except a minor change in Dmp1 KO mice at 2 months.
2160 Journal of Bone and Mineral Research JIANG ET AL.in situ hybridization, cell culture, and Western blot assays, to gain
insight into the roles of DMP1 in tooth development. We find that
(1) the delMut patient displayed enlarged pulp/root canals, thin
dentin, and unexpected defects in enamel formation, which is
similar to a dentinogenesis imperfecta III–like phenotype (see
below for detail discussion), (2) the targeted expression of the
delMut transgene, identical to that discovered in this patient, in
the Dmp1-null background lead to a similar but slightly milder
tooth phenotype. as observed in Dmp1-null mice, (3) mild
changes are seen in serum FGF-23 and Pi levels in delMut mice,
(4) Fgf23 mRNA is expressed in control odontoblast cells with a
muchhigherbasallevelthanthatinbonecells,(5)Fgf23mRNAin
Dmp1-null odontoblast cells is upregulated, and reexpression of
DMP1 in these Dmp1-null cells restores its original level, and (6)
thedelMutrecombinantDMP1isabletoactivateMAPKsignaling
but much less potently than WT DMP1. Overall, these results
suggest that the delMut molecule remains a partial DMP1
function. In addition, the DI III–like phenotype observed in the
delMut patient may be due to a second mutation or an as-yet-
undeterminedgeneticmodifierclosely linked toDMP1 orrelated
to the underlying dentin defect itself. The latter explanation is
supported by the fact that abnormal dentin mineralization
impairs development of the dentin enamel junction, which
subsequentlycanaffect enamelformation. Our dataalso support
a hypothesis that odontoblast cells play a role in control FGF-23
regulation during early postnatal development.
Currently, there are two ways to produce a mutant mouse
model.Thefirstapproachistogeneratethetargetedmutationto
the locus where the endogenous Dmp1 is located by using a
classic homologous recombination technique. The second
option is to overexpress the mutant Dmp1, under the control
of a promoter highly active in bone and dentin, in a wild-type
backgroundorintheDmp1-nullbackground. Wechosethelatter
based on the following: (1) DMP1 is expressed in both hard and
soft tissues during developmental processes,
(7,16,27,28) and
targeting the mutant gene in hard tissue would fit our goal,
(2) we have already generated and partially characterized Dmp1-
null mice, and generation of transgenic mouse lines harboring
the C-terminal mutant (Fig. 1B) would be straightforward with
little risk, (3) we have previously successfully rescued the Dmp1-
null phenotypes using the full-length Dmp1 cDNA under the
control of the Col1a1 promoter,
(18) which has the proper spatial-
temporal characteristics to overexpress this gene in hard tissues,
(4) varieties in DMP1 mutations identified from ARHR patients or
the DMP1 molecule with different mutations can be easily
adapted into this system by generation of new transgenic mice,
and (5) the first option, targeted mutation to the locus where
endogenous Dmp1 is located, has much higher risk partly owing
to difficulties in homologous recombination and in getting the
targeted cell into the germ line.
A significant question raised in this study is why the 1484–
1490delmutationleadstomuch moreseveredentindefectsplus
Fig. 4. The recombinant delMut protein retains a partial function of DMP1 in activation of MAPK signaling. (A) The wild type (WT) recombinant DMP1 and
the deletion mutant (MUT) proteins, collected from the conditional medium, are cleaved in vitro with a stains-all assay. (B) Activation of phosphorylated
ERK by full-length DMP1 (lasting for 10minutes), the C-terminal 57-kDa DMP1 fragment (lasting for over 30minutes), or the MUT DMP1 (lasting for
5minutes only) with both nonphosphorylated ERK and actin as internal controls.
DMP1 MUTATIONS IN HYPOPHOSPHATEMIA Journal of Bone and Mineral Research 2161an enamel phenotype that is not observed in Dmp1-null mice.
Based on our research results and the current literature (listed
below),weproposethatthedeletionDMP1mutationcontributes
only to part of the dentin phenotype and that there might
be another mutation or an as-yet-undetermined acquired gene
modifier or other factor. First, the same mutant gene in the
Dmp1-nullbackgrounddisplaysamilddentinphenotypewithout
an apparent defect in enamel (Fig. 2). It is of note that the
deletion mutant molecule remains part of DMP1 function
becausethismoleculestill canactivate MAPKsignaling, although
the effect is less potent (Fig. 4B). Second, even the homozygous
Dmp1-null mice exhibit only a dentin phenotype with no
changes in enamel.
(10,29) Third, the heterozygous alleles of the
human DMP1 mutants (or Dmp1-null mice) or overexpression of
this Dmp1 deletion mutant in the WT background display no
apparently abnormal dentin phenotype, excluding a dominant-
negative effect on tooth (data not shown). In fact, other deletion
Fig. 6. Loss of DMP1 or targeted reexpression of DMP1 has little effects
on Phex expression in odontoblast cells. (A) Phex is expressed in control
odontoblast cells (signal in red), as shown by an in situ hybridization
assay. (B–D) Deletion of DMP1 (B) or reexpression of DMP1 (C, D) has little
effects on Phex expressions in odontoblast cells.
Fig. 5. FGF-23ishigherinpulp/odontoblastcellsthaninbonecells.(A)Fgf23
is expressed in newborn pulp/odontoblast cells higher than in bone cells, as
shown by real-time RT-PCR. (B)Fgf23 is expressed in control odontoblast cells
(signal in red) at a much higher level than in bone, as shown by an in situ
hybridization assay. (C) A sharp increase in both Dmp1 KO osteocyte and
odontoblast cells. (D,E) Changes in Fgf23 mRNA in Dmp1-null osteocytes and
odontoblastcells,wherethemurineDmp1cDNAmouseisreexpressedunder
control of the 3.6-kb Col1a1 promoter (for both bone cells and odontoblast
cells, D) or under control of the Dspp promoter (for expression in odontoblast
cells only, E). Fgf23 mRNA levels are reduced in both KO odontoblast cells,
whereDMP1isreexpressed(D,E).NotethatFgf23mRNAlevelisreducedonly
in the Col1a1 DMP1 bone cells but not in the Dspp DMP1 bone cells.
2162 Journal of Bone and Mineral Research JIANG ET AL.mutant individuals from the same family display no DI III–like
phenotype. Note that this deletion mutation patient manifested
hypocalcemia in infancy that was suspected to have resulted
from vitamin D deficiency. This nutritional deficiency was
treated effectively. Whether the early nutritional deficiency
affected enamel development in this patient remains unknown.
Lastly, an ARHP kindred family with three affected individuals,
in which a novel homozygous frame-shift mutation (c.485Tdel;
p.Glu163ArgfsX53) in exon 6 led to a premature stop codon, was
reported.
(14) These three patients showed a mild dentin defect
with little change in enamel. These data are in agreement with
our mutant mouse data.
The next question is, What caused the dentinogenesis
imperfecta III–like phenotype in the delMut patient (Fig. 2D)?
It is known that the most common gene mutation that leads to
dentinogenesis imperfecta is the DSPP gene, whose mutations
could lead to a dominant dentinogenesis imperfecta II or III
phenotype.
(30-33) However, we do not believe that a DSPP gene
mutation is likely involved because other ARHR individuals do
notshow such severetooth phenotypes. Our current speculation
is that the DMP1 deletion mutation triggers changes in the
adjacent locus that result in an as-yet-undetermined acquired
gene modification. This patient also had vitamin D deficiency in
infancy, as discussed, which may have had an effect.
Another possibility for the phenotype difference is that it is
due to species differences between humans and mice. One
example is DSSP mutations. In humans, heterozygous DSPP
mutations display a dominant pathologic phenotype such as a
dentinogenesis imperfecta syndrome.
(30-33) On the other hand,
there is no apparent phenotype in heterozygous Dspp-null mice,
and the dentin defects occur only in homozygous mice.
(34)
There is also a spatial-temporal difference in the endogenous
DMP1 promoter activity necessarily functional in the human
population compared with the exogenous, randomly inserted
Col1a1-mutant Dmp1 transgene used in mice. In other words,
we chose a transgenic animal approach (rather than a targeted
knock-in) and used the Col1a1 promoter (rather than a Dmp1
promoter), and the promoter activity is necessarily different in
these mutant animals. The targeted-insertion approach was not
used here but may have given a phenotype in mice more closely
resembling that of the human population. The dentin abnorm-
alities themselves may affect enamel formation, yet another
potential cause for the abnormal enamel findings in this patient.
A final intriguing issue is that expressions of FGF-23 (a newly
discovered factor for control of phosphate reabsorption in the
kidney) in odontoblast cells may contribute to phosphate home-
ostasis regulation during early postnatal development. It is well
documentedthatFGF-23isreleasedmainlyfrombonecells.
(24)Here,
both our in vitro and in vivo data showed that the level of Fgf23
mRNA in odontoblasts is much higher than that in bone cells
(Fig. 5A). Note that mouse molars are fully mature at the age of
approximately 8 weeks, when the odontoblast cells are no longer
active. This may explain in part why the serum level of FGF-23 is
higher ( 350pg/mL) in 2-week-old pups than in 7-week-old mice
( 100pg/mL; Dr. Baozhi Yuan, University of Wisconsin–Madison,
personal communication). Furthermore, loss of Dmp1 leads to an
upregulation of Fgf23, and overexpression of Dmp1 in the null
background results in downregulation of Fgf23 (Fig. 5B–D). Taken
together, these findings support a hypothesis that the odontoblast
cell,asanendocrinecell,maycontributetoFGF-23regulationduring
early postnatal development. However, the odontoblast mass is
much smaller than that of bone cells. This regulation of Pi
homeostasis is likely very limited.
In summary, the successful generation and characterization
of a ARHR delMut model provides a powerful tool for studies
of the pathophysiologic process of this disease. Our initial study
suggests that DMP1 mutations are responsible for the defects
in dentinogenesis and that the severe defect in both dentin and
enamelinthedelMutpatientislikelyduetoanas-yet-undetermined
acquired gene modifier or other unidentified factor. Our studies on
expression patterns of FGF-23 in odontoblast cells support a new
notion that odontoblasts participate in control of FGF-23 expression
during early postnatal development.
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